LTPA2018017I1 - Žmogaus CGRP receptorių rišantys antikūnai - Google Patents

Žmogaus CGRP receptorių rišantys antikūnai

Info

Publication number: LTPA2018017I1
Authority: LT; Lithuania
Prior art keywords: receptor binding; binding antibodies; cgrp receptor; human cgrp; human
Prior art date: 2008-12-23

Application number

LTPA2018017C

Other languages

English (en)

Original Assignee

Amgen, Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-23

Filing date

2018-12-14

Publication date

2019-01-10

2018-12-14 Application filed by Amgen, Inc filed Critical Amgen, Inc

2019-01-10 Publication of LTPA2018017I1 publication Critical patent/LTPA2018017I1/lt

2020-04-10 Publication of LTC2379594I2 publication Critical patent/LTC2379594I2/lt

Links

108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title 1
102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Mycology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)

LTPA2018017C 2008-12-23 2018-12-14 Žmogaus CGRP receptorių rišantys antikūnai LTC2379594I2 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20356908P	2008-12-23	2008-12-23
US26462209P	2009-11-25	2009-11-25
PCT/US2009/068858 WO2010075238A1 (en)	2008-12-23	2009-12-18	Human cgrp receptor binding proteins

Publications (2)

Publication Number	Publication Date
LTPA2018017I1 true LTPA2018017I1 (lt)	2019-01-10
LTC2379594I2 LTC2379594I2 (lt)	2020-04-10

Family

ID=41718325

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP16199717.6T LT3184546T (lt)	2008-12-23	2009-12-18	Antikūnai, kurie jungiasi prie žmogaus cgrp receptorių
LTEP09775072.3T LT2379594T (lt)	2008-12-23	2009-12-18	Žmogaus cgrp receptorių rišantys antikūnai
LTPA2018017C LTC2379594I2 (lt)	2008-12-23	2018-12-14	Žmogaus CGRP receptorių rišantys antikūnai

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
LTEP16199717.6T LT3184546T (lt)	2008-12-23	2009-12-18	Antikūnai, kurie jungiasi prie žmogaus cgrp receptorių
LTEP09775072.3T LT2379594T (lt)	2008-12-23	2009-12-18	Žmogaus cgrp receptorių rišantys antikūnai

Country Status (42)

Country	Link
US (7)	US9102731B2 (lt)
EP (4)	EP2379594B8 (lt)
JP (6)	JP5761805B2 (lt)
KR (4)	KR20180043850A (lt)
CN (2)	CN102348722B (lt)
AR (1)	AR074857A1 (lt)
AU (2)	AU2009330175C1 (lt)
BR (2)	BRPI0922505B1 (lt)
CA (1)	CA2746858C (lt)
CL (1)	CL2011001578A1 (lt)
CO (1)	CO6400232A2 (lt)
CR (1)	CR20110400A (lt)
CY (3)	CY1119465T1 (lt)
DK (2)	DK3184546T3 (lt)
EA (2)	EA031320B1 (lt)
ES (2)	ES2643835T3 (lt)
FI (1)	FI3569620T3 (lt)
HR (2)	HRP20171690T1 (lt)
HU (3)	HUE034506T2 (lt)
IL (2)	IL213429A (lt)
JO (2)	JO3382B1 (lt)
LT (3)	LT3184546T (lt)
LU (1)	LUC00095I2 (lt)
MA (1)	MA32982B1 (lt)
ME (1)	ME03601B (lt)
MX (1)	MX2011006804A (lt)
MY (1)	MY180564A (lt)
NL (1)	NL300961I2 (lt)
NO (2)	NO2379594T3 (lt)
NZ (2)	NZ606090A (lt)
PE (1)	PE20120427A1 (lt)
PL (2)	PL2379594T3 (lt)
PT (2)	PT2379594T (lt)
RS (2)	RS59343B1 (lt)
SG (2)	SG10201401879TA (lt)
SI (2)	SI3184546T1 (lt)
SM (1)	SMT201700504T1 (lt)
TN (1)	TN2011000283A1 (lt)
TW (4)	TWI754176B (lt)
UA (1)	UA108066C2 (lt)
WO (1)	WO2010075238A1 (lt)
ZA (1)	ZA201105418B (lt)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8007794B2 (en)	2005-11-14	2011-08-30	Rinat Neuroscience Corporation	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2008330125B2 (en) *	2007-11-21	2012-11-22	Amgen Inc.	Wise binding antibodies and epitopes
EP2265287B1 (en)	2008-03-04	2018-09-05	Teva Pharmaceuticals International GmbH	Methods of treating chronic pain
JO3382B1 (ar) *	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (en)	2009-08-28	2011-03-03	Rinat Neuroscience Corporation	Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
SG194974A1 (en)	2011-05-20	2013-12-30	Alderbio Holdings Llc	Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
PE20141787A1 (es)	2011-05-20	2014-12-07	Alderbio Holdings Llc	Composiciones anti-cgrp y uso de las mismas
SMT202400511T1 (it)	2011-05-20	2025-01-14	H Lundbeck As	Uso di anticorpi anti-cgrp e frammenti di anticorpi per prevenire o inibire la fotofobia o l'avversione alla luce in soggetti che ne hanno bisogno, in particolare nei soggetti che soffrono di emicrania
AU2014236867A1 (en)	2013-03-15	2015-09-24	Amgen Inc.	Methods and compositions relating to anti-CCR7 antigen binding proteins
KR102215405B1 (ko) *	2013-03-15	2021-02-10	암젠 인크	인간 pac1 항체
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
ES2815099T3 (es)	2013-08-05	2021-03-29	Twist Bioscience Corp	Genotecas sintetizadas de novo
CA2920894C (en)	2013-10-24	2023-03-14	Amgen Inc.	Injector and method of assembly
MX2016005315A (es)	2013-10-24	2016-08-11	Amgen Inc	Sistema de administracion de farmacos con control sensible a la temperatura.
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
KR102274964B1 (ko)	2014-03-21	2021-07-09	테바 파마슈티컬스 인터내셔널 게엠베하	칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2945026C (en)	2014-05-07	2023-10-10	Amgen Inc.	Autoinjector with shock reducing elements
IL297356A (en)	2014-06-03	2022-12-01	Amgen Inc	Controllable drug delivery system and method of use
JP6956631B2 (ja)	2014-09-15	2021-11-02	アムジェンインコーポレイテッド	二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
WO2016061220A2 (en)	2014-10-14	2016-04-21	Amgen Inc.	Drug injection device with visual and audio indicators
JP2017538512A (ja)	2014-12-19	2017-12-28	アムジエン・インコーポレーテツド	ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
US10799630B2 (en)	2014-12-19	2020-10-13	Amgen Inc.	Drug delivery device with proximity sensor
CA2973964A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
US10669304B2 (en)	2015-02-04	2020-06-02	Twist Bioscience Corporation	Methods and devices for de novo oligonucleic acid assembly
WO2016133947A1 (en)	2015-02-17	2016-08-25	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en)	2015-02-27	2021-12-15	Amgen Inc.	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2016172377A1 (en)	2015-04-21	2016-10-27	Twist Bioscience Corporation	Devices and methods for oligonucleic acid library synthesis
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
WO2016183479A1 (en)	2015-05-13	2016-11-17	The Board Of Regents Of The University Of Oklahoma	Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
GB2557529A (en)	2015-09-18	2018-06-20	Twist Bioscience Corp	Oligonucleic acid variant libraries and synthesis thereof
KR102794025B1 (ko)	2015-09-22	2025-04-09	트위스트 바이오사이언스 코포레이션	핵산 합성을 위한 가요성 기판
ES2755717T3 (es)	2015-12-09	2020-04-23	Amgen Inc	Autoinyector con tapa de señalización
WO2017120178A1 (en)	2016-01-06	2017-07-13	Amgen Inc.	Auto-injector with signaling electronics
WO2017136607A1 (en)	2016-02-02	2017-08-10	Fred Hutchinson Cancer Research Center	Anti-ror1 antibodies and uses thereof
US11200298B2 (en)	2016-03-15	2021-12-14	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
SG11201808630WA (en)	2016-04-15	2018-10-30	Alder Biopharmaceuticals Inc	Humanized anti-pacap antibodies and uses thereof
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
MX2018013616A (es)	2016-05-13	2019-02-21	Amgen Inc	Montaje de cubierta protectora de vial.
EP3458988B1 (en)	2016-05-16	2023-10-18	Amgen Inc.	Data encryption in medical devices with limited computational capability
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en)	2016-07-01	2022-03-29	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
US10417457B2 (en)	2016-09-21	2019-09-17	Twist Bioscience Corporation	Nucleic acid based data storage
KR20190066607A (ko)	2016-09-23	2019-06-13	테바 파마슈티컬스 인터내셔널 게엠베하	불응성 편두통의 치료
CA3037661A1 (en)	2016-09-23	2018-03-29	Teva Pharmaceuticals International Gmbh	Treating cluster headache
US20200261643A1 (en)	2016-10-25	2020-08-20	Amgen Inc.	On-body injector
US11993645B2 (en)	2017-01-11	2024-05-28	The Board Of Trustees Of The Leland Stanford Junior University	Compositions comprising R-Spondin (RSPO) surrogate molecules
MX2019008432A (es)	2017-01-17	2019-11-18	Amgen Inc	Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
WO2018140821A1 (en)	2017-01-26	2018-08-02	Surrozen, Inc.	Tissue-specific wnt signal enhancing molecules and uses thereof
US11752258B2 (en)	2017-02-17	2023-09-12	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019009755A (es)	2017-02-17	2019-10-07	Amgen Inc	Mecanismo de insercion para dispositivo de suministro de farmacos.
KR102723464B1 (ko)	2017-02-22	2024-10-28	트위스트 바이오사이언스 코포레이션	핵산 기반 데이터 저장
CN110621343A (zh) *	2017-03-02	2019-12-27	贝丝以色列女执事医疗中心	选择对针对降钙素基因相关肽的抗体有反应的头痛患者
JP2020508803A (ja)	2017-03-06	2020-03-26	アムジエン・インコーポレーテツド	作動防止特徴部を備える薬物送達デバイス
US11571511B2 (en)	2017-03-07	2023-02-07	Amgen Inc.	Insertion mechanism and method of inserting a needle of a drug delivery device
MX2019010671A (es)	2017-03-09	2019-10-21	Amgen Inc	Mecanismo de insercion para dispositivo de administracion de farmacos.
JP7118993B2 (ja)	2017-03-28	2022-08-16	アムジエン・インコーポレーテツド	プランジャーロッド・シリンジアセンブリシステム及び方法
EP3634546A1 (en)	2017-06-08	2020-04-15	Amgen Inc.	Torque driven drug delivery device
AU2018280054B2 (en)	2017-06-08	2023-07-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
AU2018288604B2 (en)	2017-06-22	2023-12-21	Amgen Inc.	Device activation impact/shock reduction
MX2019015479A (es)	2017-06-23	2020-02-20	Amgen Inc	Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
JP7408398B2 (ja)	2017-07-14	2024-01-05	アムジエン・インコーポレーテツド	二重ねじりばねシステムを有する針挿入後退システム
EP3655063A1 (en)	2017-07-21	2020-05-27	Amgen Inc.	Gas permeable sealing member for drug container and methods of assembly
MA49676A (fr)	2017-07-25	2020-06-03	Amgen Inc	Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
MA49677A (fr)	2017-07-25	2021-04-21	Amgen Inc	Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
US12318593B2 (en)	2017-08-09	2025-06-03	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en)	2017-08-18	2020-06-24	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
MA50611A (fr)	2017-10-04	2020-08-12	Amgen Inc	Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
MA50614A (fr)	2017-10-06	2020-08-12	Amgen Inc	Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3694578A1 (en)	2017-10-09	2020-08-19	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
US10894242B2 (en)	2017-10-20	2021-01-19	Twist Bioscience Corporation	Heated nanowells for polynucleotide synthesis
IL273582B2 (en)	2017-11-03	2024-12-01	Amgen Inc	Systems and approaches for sterilizing a drug delivery device
MA50553A (fr)	2017-11-06	2020-09-16	Amgen Inc	Dispositif d'administration de médicament avec détection de positionnement et de débit
EP3707075A1 (en)	2017-11-06	2020-09-16	Amgen Inc.	Fill-finish assemblies and related methods
EP3706826A1 (en)	2017-11-10	2020-09-16	Amgen Inc.	Plungers for drug delivery devices
CA3079540A1 (en)	2017-11-16	2019-05-23	Amgen Inc.	Door latch mechanism for drug delivery device
EP3737699A1 (en)	2018-01-12	2020-11-18	Amgen Inc.	Pac1 antibodies and uses thereof
SG11202009629YA (en)	2018-04-02	2020-10-29	Amgen Inc	Erenumab compositions and uses thereof
BR112020020854A2 (pt)	2018-04-12	2021-01-19	Amgen Inc.	Métodos para produzir composições de proteínas estáveis
CA3100739A1 (en)	2018-05-18	2019-11-21	Twist Bioscience Corporation	Polynucleotides, reagents, and methods for nucleic acid hybridization
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
MA53379A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
EP3826699A1 (en)	2018-07-24	2021-06-02	Amgen Inc.	Delivery devices for administering drugs
WO2020023220A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
US12109389B2 (en)	2018-07-31	2024-10-08	Amgen Inc.	Fluid path assembly for a drug delivery device
AU2019347710B2 (en)	2018-09-24	2025-05-08	Amgen Inc.	Interventional dosing systems and methods
AU2019350660B2 (en)	2018-09-28	2024-09-26	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
US12156991B2 (en)	2018-10-02	2024-12-03	Amgen Inc.	Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en)	2018-10-05	2020-04-09	Amgen Inc.	Drug delivery device having dose indicator
AU2019359801B2 (en)	2018-10-15	2025-01-02	Amgen Inc.	Platform assembly process for drug delivery device
EP3866890A1 (en)	2018-10-15	2021-08-25	Amgen Inc.	Drug delivery device having damping mechanism
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
AU2019370159B2 (en)	2018-11-01	2025-05-29	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
CN119708086A (zh)	2018-12-26	2025-03-28	特韦斯特生物科学公司	高度准确的从头多核苷酸合成
JOP20210156A1 (ar)	2019-01-08	2023-01-30	H Lundbeck As	علاج إسعافي وعلاج سريع للصداع باستخدام أجسام مضادة لـ cgrp
KR20210143766A (ko) *	2019-02-26	2021-11-29	트위스트 바이오사이언스 코포레이션	Glp1 수용체에 대한 변이체 핵산 라이브러리
EP3958934B1 (en)	2019-04-24	2025-04-09	Amgen Inc.	Syringe sterilization verification assemblies and methods
WO2020239014A1 (zh) *	2019-05-30	2020-12-03	山东博安生物技术有限公司	抗cgrp抗体及其应用
WO2020264384A1 (en)	2019-06-28	2020-12-30	Amgen Inc.	Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
MX2022002149A (es)	2019-08-23	2022-03-17	Amgen Inc	Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CN115003697A (zh)	2019-09-23	2022-09-02	特韦斯特生物科学公司	Crth2的变异核酸文库
AU2020355027A1 (en)	2019-09-23	2022-04-21	Twist Bioscience Corporation	Antibodies that bind CD3 Epsilon
CA3198268A1 (en)	2020-11-16	2022-05-19	Surrozen Operating, Inc.	Liver-specific wnt signal enhancing molecules and uses thereof
JP2024509165A (ja)	2021-03-02	2024-02-29	シージーアールピーダイアグノスティクスゲーエムベーハー	片頭痛の治療及び／又は発生の低減
MX2023013640A (es)	2021-05-21	2023-11-30	Amgen Inc	Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
JP2025515038A (ja) *	2022-05-05	2025-05-13	アムジェンインコーポレイテッド	Ｄｌｌ３及びｃｄ３に結合するヘテロ多量体
TW202432600A (zh)	2022-11-07	2024-08-16	美商安進公司	用於治療肥胖症之方法

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JPH02229119A (ja)	1989-02-28	1990-09-11	Toyo Jozo Co Ltd	動脈硬化予防および治療剤
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
WO1991018982A1 (en)	1990-06-05	1991-12-12	Immunex Corporation	Type ii interleukin-1 receptors
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
CA2105984C (en)	1991-03-11	2002-11-26	Milton J. Cormier	Cloning and expression of renilla luciferase
JPH06508035A (ja)	1991-06-14	1994-09-14	ディーエヌエックス　コーポレーション	トランスジェニックブタにおけるヒトヘモグロビンの生産
CA2113113A1 (en)	1991-07-08	1993-01-21	Simon W. Kantor	Thermotropic liquid crystal segmented block copolymer
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
DK0640131T3 (da) *	1992-03-17	1999-11-01	Novartis Ag	Gensplejsere antistoffer
ATE381614T1 (de)	1992-07-24	2008-01-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
DK0672141T3 (da)	1992-10-23	2003-06-10	Immunex Corp	Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5766880A (en) *	1992-10-27	1998-06-16	Queen's University At Kingston	Isolated nucleic acid molecules encoding multidrug resistance proteins
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
ATE400651T1 (de)	1993-09-10	2008-07-15	Univ Columbia	Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
WO1996003993A2 (en)	1994-08-05	1996-02-15	The Rockefeller University	Modulation of thymocyte and t cell functional activity
AU7953194A (en)	1994-08-16	1996-03-07	Human Genome Sciences, Inc.	Calcitonin receptor
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
AU6596096A (en)	1996-07-23	1998-02-10	Smithkline Beecham Corporation	Calcitonin gene-related peptide receptor component factor (houdc44)
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6255455B1 (en) *	1996-10-11	2001-07-03	The Trustees Of The University Of Pennsylvania	Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
AU5702298A (en)	1996-12-03	1998-06-29	Abgenix, Inc.	Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
WO1998026277A2 (en)	1996-12-12	1998-06-18	Prolume, Ltd.	Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en)	1997-01-31	1998-07-31	Stephen William Watson Michnick	Protein fragment complementation assay for the detection of protein-protein interactions
DE19732944A1 (de)	1997-07-31	1999-02-04	Thomae Gmbh Dr K	Peptidische CGRP-Antagonisten
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
JP2002507410A (ja)	1998-03-27	2002-03-12	プロルーム・リミテッド	ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US6268474B1 (en)	1998-04-30	2001-07-31	Creighton University	Peptide antagonists of CGRP-receptor superfamily and methods of use
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
US20020142374A1 (en)	1998-08-17	2002-10-03	Michael Gallo	Generation of modified molecules with increased serum half-lives
WO2001040794A1 (en) *	1999-12-02	2001-06-07	Myriad Genetics, Inc.	Protein-protein interactions
US20020090646A1 (en)	2000-05-03	2002-07-11	Amgen Inc.	Calcitonin-related molecules
FR2821080B1 (fr)	2001-02-20	2003-12-19	Sanofi Synthelabo	Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
WO2002102973A2 (en)	2001-06-20	2002-12-27	Prochon Biotech Ltd.	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1438325B1 (en) *	2001-09-27	2009-12-30	Merck & Co., Inc.	Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
PT1576112E (pt) *	2002-01-18	2012-05-25	Zymogenetics Inc	Multímeros de receptor de citocina zcytor17
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20040110170A1 (en)	2002-05-18	2004-06-10	The Regents Of The University Of California	Cloning and characterization of calcitonin gene related peptide receptors
US20070071744A1 (en) *	2002-06-07	2007-03-29	Gotz Munch	Agents which bind to epitopes of glycoprotein VI
BR0313388A (pt) *	2002-08-12	2005-07-05	Birkir Sveinsson	Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
US20040176577A1 (en) *	2002-09-10	2004-09-09	Eva Rojer	Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en)	2003-04-29	2004-11-11	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CN1961000B (zh)	2004-02-11	2011-05-04	安米林药品公司	具有可选择特性的杂合多肽
US7423128B2 (en) *	2004-11-03	2008-09-09	Amgen Fremont Inc.	Anti-properdin antibodies, and methods for making and using same
RS52036B (en)	2004-12-21	2012-04-30	Medimmune Limited	ANGIOPOETIN-2 ANTIBODIES AND ITS USES
EP1900374B1 (en)	2005-06-16	2014-03-12	Takayuki Shindo	Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US8007794B2 (en)	2005-11-14	2011-08-30	Rinat Neuroscience Corporation	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007076336A1 (en) *	2005-12-22	2007-07-05	Eli Lilly And Company	Treatment of migraine with anti-cgrp antibodies
TW200815474A (en) *	2006-08-03	2008-04-01	Astrazeneca Ab	Antibodies alphaVbeta6 and uses thereof
GB0708002D0 (en)	2007-04-25	2007-06-06	Univ Sheffield	Antibodies
KR101304085B1 (ko)	2008-03-04	2013-09-05	라브리스 바이올로직스 인코포레이티드	염증성 통증의 치료 방법
FR2934597B1 (fr)	2008-07-31	2013-04-19	Univ Aix Marseille Ii	Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (en)	2009-08-28	2011-03-03	Rinat Neuroscience Corporation	Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JP5782185B2 (ja)	2012-06-01	2015-09-24	日本電信電話株式会社	パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof
JP6956631B2 (ja)	2014-09-15	2021-11-02	アムジェンインコーポレイテッド	二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
US11385238B2 (en)	2017-06-30	2022-07-12	Amgen Inc.	Methods of protein clips recovery
SG11202009629YA (en)	2018-04-02	2020-10-29	Amgen Inc	Erenumab compositions and uses thereof

2009
- 2009-12-02 JO JOP/2009/0461A patent/JO3382B1/ar active
- 2009-12-18 RS RSP20191122 patent/RS59343B1/sr unknown
- 2009-12-18 CA CA2746858A patent/CA2746858C/en active Active
- 2009-12-18 AU AU2009330175A patent/AU2009330175C1/en active Active
- 2009-12-18 EP EP09775072.3A patent/EP2379594B8/en active Active
- 2009-12-18 SG SG10201401879TA patent/SG10201401879TA/en unknown
- 2009-12-18 HU HUE09775072A patent/HUE034506T2/en unknown
- 2009-12-18 KR KR1020187011418A patent/KR20180043850A/ko not_active Ceased
- 2009-12-18 UA UAA201109219A patent/UA108066C2/ru unknown
- 2009-12-18 EP EP16199717.6A patent/EP3184546B8/en active Active
- 2009-12-18 EP EP19181187.6A patent/EP3569620B1/en active Active
- 2009-12-18 SM SM20170504T patent/SMT201700504T1/it unknown
- 2009-12-18 EA EA201100892A patent/EA031320B1/ru active Protection Beyond IP Right Term
- 2009-12-18 MA MA34035A patent/MA32982B1/fr unknown
- 2009-12-18 KR KR1020117017235A patent/KR101740615B1/ko active Active
- 2009-12-18 ES ES09775072.3T patent/ES2643835T3/es active Active
- 2009-12-18 NZ NZ606090A patent/NZ606090A/en unknown
- 2009-12-18 FI FIEP19181187.6T patent/FI3569620T3/fi active
- 2009-12-18 MY MYPI2011002908A patent/MY180564A/en unknown
- 2009-12-18 DK DK16199717.6T patent/DK3184546T3/da active
- 2009-12-18 LT LTEP16199717.6T patent/LT3184546T/lt unknown
- 2009-12-18 BR BRPI0922505-6A patent/BRPI0922505B1/pt active IP Right Grant
- 2009-12-18 PT PT97750723T patent/PT2379594T/pt unknown
- 2009-12-18 BR BR122020010360-4A patent/BR122020010360B1/pt active IP Right Grant
- 2009-12-18 CN CN200980157606.3A patent/CN102348722B/zh active Active
- 2009-12-18 NO NO09775072A patent/NO2379594T3/no unknown
- 2009-12-18 HU HUE16199717A patent/HUE045966T2/hu unknown
- 2009-12-18 RS RS20171121A patent/RS56567B1/sr unknown
- 2009-12-18 EP EP25165937.1A patent/EP4585264A2/en active Pending
- 2009-12-18 DK DK09775072.3T patent/DK2379594T3/en active
- 2009-12-18 KR KR1020197013698A patent/KR20190054181A/ko not_active Ceased
- 2009-12-18 PE PE2011001269A patent/PE20120427A1/es active IP Right Grant
- 2009-12-18 PT PT16199717T patent/PT3184546T/pt unknown
- 2009-12-18 SI SI200931989T patent/SI3184546T1/sl unknown
- 2009-12-18 WO PCT/US2009/068858 patent/WO2010075238A1/en active Application Filing
- 2009-12-18 ES ES16199717T patent/ES2746571T3/es active Active
- 2009-12-18 NZ NZ623541A patent/NZ623541A/en unknown
- 2009-12-18 KR KR1020177013822A patent/KR101853393B1/ko active Active
- 2009-12-18 EA EA201891500A patent/EA201891500A3/ru unknown
- 2009-12-18 HR HRP20171690TT patent/HRP20171690T1/hr unknown
- 2009-12-18 SG SG2011045556A patent/SG172307A1/en unknown
- 2009-12-18 MX MX2011006804A patent/MX2011006804A/es active IP Right Grant
- 2009-12-18 CN CN201610333096.2A patent/CN106084045B/zh active Active
- 2009-12-18 PL PL09775072T patent/PL2379594T3/pl unknown
- 2009-12-18 PL PL16199717T patent/PL3184546T3/pl unknown
- 2009-12-18 JP JP2011543606A patent/JP5761805B2/ja active Active
- 2009-12-18 ME MEP-2019-240A patent/ME03601B/me unknown
- 2009-12-18 US US12/642,711 patent/US9102731B2/en active Active
- 2009-12-18 LT LTEP09775072.3T patent/LT2379594T/lt unknown
- 2009-12-18 SI SI200931756T patent/SI2379594T1/sl unknown
- 2009-12-22 TW TW108136419A patent/TWI754176B/zh active
- 2009-12-22 AR ARP090105053A patent/AR074857A1/es active IP Right Grant
- 2009-12-22 TW TW110149087A patent/TW202241950A/zh unknown
- 2009-12-22 TW TW105134382A patent/TWI688403B/zh active
- 2009-12-22 TW TW098144377A patent/TWI574697B/zh active
2011
- 2011-06-01 TN TN2011000283A patent/TN2011000283A1/fr unknown
- 2011-06-06 IL IL213429A patent/IL213429A/en active Protection Beyond IP Right Term
- 2011-06-23 CL CL2011001578A patent/CL2011001578A1/es unknown
- 2011-07-15 CO CO11088995A patent/CO6400232A2/es active IP Right Grant
- 2011-07-22 ZA ZA2011/05418A patent/ZA201105418B/en unknown
- 2011-07-22 CR CR20110400A patent/CR20110400A/es unknown
2012
- 2012-09-12 US US13/612,615 patent/US20130071410A1/en not_active Abandoned
2013
- 2013-04-10 AU AU2013205271A patent/AU2013205271C1/en active Active
2014
- 2014-08-12 JP JP2014164088A patent/JP6261132B2/ja active Active
2015
- 2015-06-26 US US14/752,493 patent/US9862771B2/en active Active
- 2015-11-09 JP JP2015219157A patent/JP2016026224A/ja not_active Withdrawn
2016
- 2016-01-26 IL IL243784A patent/IL243784A/en active IP Right Grant
2017
- 2017-08-28 CY CY20171100901T patent/CY1119465T1/el unknown
- 2017-11-28 US US15/824,827 patent/US20180142029A1/en not_active Abandoned
2018
- 2018-12-04 CY CY2018032C patent/CY2018032I2/el unknown
- 2018-12-10 HU HUS1800047C patent/HUS1800047I1/hu unknown
- 2018-12-12 NL NL300961C patent/NL300961I2/nl unknown
- 2018-12-14 LT LTPA2018017C patent/LTC2379594I2/lt unknown
- 2018-12-17 NO NO2018042C patent/NO2018042I1/no unknown
- 2018-12-20 LU LU00095C patent/LUC00095I2/fr unknown
- 2018-12-28 JP JP2018246704A patent/JP2019062907A/ja not_active Withdrawn
2019
- 2019-02-07 JO JOP/2019/0017A patent/JOP20190017B1/ar active
- 2019-07-25 HR HRP20191341TT patent/HRP20191341T8/hr unknown
- 2019-09-19 CY CY20191100989T patent/CY1122658T1/el unknown
2020
- 2020-11-27 JP JP2020196689A patent/JP2021036912A/ja not_active Withdrawn
- 2020-12-03 US US17/111,453 patent/US12134652B2/en active Active
- 2020-12-03 US US17/111,442 patent/US12122841B2/en active Active
2023
- 2023-06-21 JP JP2023101810A patent/JP7584577B2/ja active Active
2024
- 2024-10-02 US US18/904,787 patent/US20250129172A1/en active Pending

Also Published As

Publication number	Publication date
CN106084045B (zh)	2020-02-11
FI3569620T3 (fi)	2025-07-15
US20250129172A1 (en)	2025-04-24
JP2016026224A (ja)	2016-02-12
JP2021036912A (ja)	2021-03-11
PL3184546T3 (pl)	2019-12-31
NZ623541A (en)	2015-12-24
AU2009330175A1 (en)	2011-06-23
CR20110400A (es)	2011-10-12
KR20190054181A (ko)	2019-05-21
NO2379594T3 (lt)	2018-01-06
HRP20171690T1 (hr)	2017-12-15
KR101853393B1 (ko)	2018-05-02
EA031320B1 (ru)	2018-12-28
EP4585264A2 (en)	2025-07-16
SG172307A1 (en)	2011-07-28
SI2379594T1 (sl)	2017-12-29
US20210179722A1 (en)	2021-06-17
AU2009330175C1 (en)	2018-10-04
CY2018032I1 (el)	2019-07-10
ME03601B (me)	2020-07-20
RS56567B1 (sr)	2018-02-28
CA2746858A1 (en)	2010-07-01
TW202026312A (zh)	2020-07-16
SI3184546T1 (sl)	2019-09-30
SG10201401879TA (en)	2014-06-27
TWI574697B (zh)	2017-03-21
TW202241950A (zh)	2022-11-01
IL243784A (en)	2016-11-30
EA201100892A1 (ru)	2012-01-30
KR101740615B1 (ko)	2017-05-26
JP2014210815A (ja)	2014-11-13
ES2746571T3 (es)	2020-03-06
RS59343B1 (sr)	2019-10-31
US20100172895A1 (en)	2010-07-08
LUC00095I1 (lt)	2018-12-28
US20210179723A1 (en)	2021-06-17
EP3184546B1 (en)	2019-07-17
EA201891500A2 (ru)	2018-11-30
SMT201700504T1 (it)	2018-01-11
EP2379594B1 (en)	2017-08-09
US9102731B2 (en)	2015-08-11
MY180564A (en)	2020-12-02
JOP20190017B1 (ar)	2023-03-28
HRP20191341T1 (hr)	2019-10-18
NO2018042I1 (no)	2018-12-17
LT3184546T (lt)	2019-09-10
TW201032823A (en)	2010-09-16
JP5761805B2 (ja)	2015-08-12
LT2379594T (lt)	2017-11-27
TW201703796A (zh)	2017-02-01
US12122841B2 (en)	2024-10-22
JP6261132B2 (ja)	2018-01-17
DK2379594T3 (en)	2017-10-30
IL243784A0 (en)	2016-04-21
NL300961I2 (nl)	2019-01-15
HUS1800047I1 (hu)	2018-12-28
LTC2379594I2 (lt)	2020-04-10
BR122020010360B1 (pt)	2022-08-16
EP2379594A1 (en)	2011-10-26
MA32982B1 (fr)	2012-01-02
US20150376286A1 (en)	2015-12-31
TWI688403B (zh)	2020-03-21
CA2746858C (en)	2017-10-03
IL213429A (en)	2016-02-29
JO3382B1 (ar)	2019-03-13
US20130071410A1 (en)	2013-03-21
EP2379594B8 (en)	2020-12-30
JP2019062907A (ja)	2019-04-25
PT2379594T (pt)	2017-11-16
AU2013205271B2 (en)	2016-07-14
AU2013205271C1 (en)	2018-10-04
EA201891500A3 (ru)	2019-03-29
KR20170061182A (ko)	2017-06-02
NZ606090A (en)	2014-08-29
PT3184546T (pt)	2019-09-16
KR20180043850A (ko)	2018-04-30
HUE045966T2 (hu)	2020-01-28
HUE034506T2 (en)	2018-02-28
ZA201105418B (en)	2012-02-29
JOP20190017A1 (ar)	2017-06-16
CN102348722A (zh)	2012-02-08
AR074857A1 (es)	2011-02-16
LUC00095I2 (lt)	2019-12-24
KR20110106409A (ko)	2011-09-28
US12134652B2 (en)	2024-11-05
AU2013205271A1 (en)	2013-05-02
AU2009330175B2 (en)	2014-01-16
PL2379594T3 (pl)	2018-01-31
PE20120427A1 (es)	2012-05-13
CN102348722B (zh)	2016-06-08
JP2023116783A (ja)	2023-08-22
ES2643835T3 (es)	2017-11-24
CL2011001578A1 (es)	2012-01-20
HRP20191341T8 (hr)	2020-02-07
MX2011006804A (es)	2011-09-27
UA108066C2 (uk)	2015-03-25
TN2011000283A1 (en)	2012-12-17
JP7584577B2 (ja)	2024-11-15
IL213429A0 (en)	2011-07-31
EP3184546B8 (en)	2019-10-30
EP3184546A1 (en)	2017-06-28
US20180142029A1 (en)	2018-05-24
US9862771B2 (en)	2018-01-09
CY2018032I2 (el)	2019-07-10
DK3184546T3 (da)	2019-09-30
EP3569620A1 (en)	2019-11-20
WO2010075238A1 (en)	2010-07-01
BRPI0922505A2 (pt)	2016-07-05
EP3569620B1 (en)	2025-05-07
JP2012513214A (ja)	2012-06-14
BRPI0922505B1 (pt)	2021-08-03
CY1122658T1 (el)	2021-03-12
CO6400232A2 (es)	2012-03-15
CN106084045A (zh)	2016-11-09
CY1119465T1 (el)	2018-03-07
TWI754176B (zh)	2022-02-01

Publication	Publication Date	Title
LTC2379594I2 (lt)	2020-04-10	Žmogaus CGRP receptorių rišantys antikūnai
CY2022023I1 (el)	2023-01-05	Ανταγωνιστες cgrp υποδοχεα
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY2018003I2 (el)	2018-09-05	Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4
EP2349274A4 (en)	2014-12-17	CONJUGATES OF ANTIFOLATES BINDING THE FOLATE RECEPTOR
BRPI0923359A2 (pt)	2015-07-21	Anticorpos anti-igf
DK2131860T3 (da)	2014-01-13	Anti-sclerostin-antistoffer
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
PL2185589T3 (pl)	2016-09-30	Środki wiążące receptor regionu stałego Fc immunoglobuliny
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
ZA201008335B (en)	2014-04-30	Interleukin-21 receptor binding proteins
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb